IP Library Granted Patent US 9,006,186
Granted Patent B2
US 9,006,186 · App. 14/058,461 · Granted Apr 14, 2015

Selective targeting agents for mitochondria

Inventors: Peter Wipf (Pittsburgh, PA); Jingbo Xiao (Pittsburgh, PA); Mitchell P. Fink (Pittsburgh, PA); Valerian Kagan (Pittsburgh, PA); Yulia Tyurina (Pittsburgh, PA); Anthony J. Kanai (Pittsburgh, PA)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
C07K5/10C07K7/06A61K31/555A61K31/7034A61K31/7048A61K47/481A61K47/48246C07K5/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,006,186
App. No.
14/058,461
Granted
Apr 14, 2015
Kind
B2
Abstract

The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargoes which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the β-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient.

Claims (24)

1. A method for delivering a moiety to mitochondria of a patient comprising administering to a patient a mitochondria-targeting compound comprising a membrane-active fragment of gramicidin S or an E-alkene isostere thereof conjugated to a moiety, wherein the gramicidin S fragment or E-alkene isostere thereof has the sequence Leu- D Phe-Pro-Val-Orn, and wherein the moiety is a reactive-oxygen species (ROS) scavenger.

2. The method of claim 1 , in which the gramicidin S fragment or E-alkene isostere thereof comprises a β-turn.

3. The method of claim 1 , in which an amine of the gramicidin S fragment or E-alkene isostere thereof is acylated.

4. The method of claim 1 , in which an amine of the gramicidin S fragment or E-alkene isostere thereof is acylated with Boc and/or Cbz.

5. The method of claim 1 , in which the moiety is a nitroxide reactive-oxygen species (ROS) scavenger.

6. The method of claim 1 , in which the moiety is TEMPO or 4-amino TEMPO.

7. The method of claim 1 , in which the moiety is conjugated to the compound of formula A:

where R is H or methyl.

8. The method of claim 7 , in which the moiety is TEMPO or 4-amino TEMPO.

9. The method of claim 1 , in which the compound is administered to treat a patient for a condition associated or caused by reactive oxygen species (ROS).

10. The method of claim 9 , in which the condition is hemorrhagic shock.

11. The method of claim 1 , wherein the gramicidin S fragment or E-alkene isostere thereof has the sequence Leu-(E)- D Phe-Pro-Val-Orn.

12. A compound comprising a membrane-active fragment of gramicidin S or an E-alkene isostere thereof conjugated to a moiety, wherein the gramicidin S fragment or E-alkene isostere thereof has the sequence Leu- D Phe-Pro-Val-Orn, and wherein the moiety is a reactive-oxygen species (ROS) scavenger.

13. The compound of claim 12 , in which the gramicidin S fragment or E-alkene isostere thereof comprises a β-turn.

14. The compound of claim 12 , in which an amine of the gramicidin S fragment or E-alkene isostere thereof is acylated.

15. The compound of claim 12 , in which an amine of the gramicidin S fragment or E-alkene isostere thereof is acylated with Boc and/or Cbz.

16. The compound of claim 12 , in which the moiety is a nitroxide reactive-oxygen species (ROS) scavenger.

17. The compound of claim 16 , in which the in which the moiety is TEMPO or 4-amino TEMPO.

18. The compound of claim 12 , wherein the gramicidin S fragment or E-alkene isostere thereof has the sequence Leu-(E)- D Phe-Pro-Val-Orn.

19. A method for delivering a moiety to mitochondria of a patient comprising administering to a patient a mitochondria-targeting compound, represented by Formula B:

conjugated to a moiety, and wherein the moiety is a reactive-oxygen species (ROS) scavenger.

20. The method of claim 19 , in which the moiety is TEMPO or 4-amino TEMPO.

21. A compound comprising Formula B:

conjugated to a moiety, and wherein the moiety is a reactive-oxygen species (ROS) scavenger.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 17, 2013
From: UNIVERSITY OF PITTSBURGH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031832/0077 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2013
From: WIPF, PETER; XIAO, JINGBO; FINK, MITCHELL P.; KAGAN, VALERIAN E.; TYURINA, YULIA; KANAI, ANTHONY J.
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 031646/0701 →
Continuity (6)
Continuation 12750891 · Mar 31, 2010
Continuation 11565779 · Dec 1, 2006
Continuation In Part 11465524 · Aug 18, 2006
Continuation In Part 11465162 · Aug 17, 2006
Provisional Application 60757044 · Jan 6, 2006
Related Publication 20140107317A1 · Apr 17, 2014